$120 Million is the total value of Lynx1 Capital Management LP's 13 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $24,211,256 | +5.4% | 3,136,173 | +0.3% | 20.18% | +1.6% |
| CABA | Sell | CABALETTA BIO INC | $20,299,765 | -22.3% | 2,454,627 | -13.1% | 16.92% | -25.1% |
| MRUS | Buy | MERUS N V | $19,646,103 | +48.6% | 1,067,723 | +24.9% | 16.38% | +43.3% |
| KNTE | Buy | KINNATE BIOPHARMA INC | $13,839,063 | +13.5% | 2,214,250 | +10.8% | 11.54% | +9.4% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $11,945,763 | +15.2% | 1,369,927 | -17.1% | 9.96% | +11.1% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $6,898,093 | +17.8% | 7,067,718 | +25.6% | 5.75% | +13.6% |
| Sell | THESEUS PHARMACEUTICALS INC | $6,759,971 | +73.1% | 761,258 | -2.9% | 5.64% | +66.9% | |
| BLU | Sell | BELLUS HEALTH INC NEW | $6,239,851 | -30.6% | 866,646 | -20.8% | 5.20% | -33.1% |
| Buy | PARDES BIOSCIENCES INC | $4,387,761 | -13.5% | 3,324,061 | +10.7% | 3.66% | -16.7% | |
| PASG | Buy | PASSAGE BIO INC | $3,263,457 | -29.5% | 3,407,598 | +1.5% | 2.72% | -32.1% |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $1,699,826 | +45.8% | 2,428,323 | +6.0% | 1.42% | +40.4% |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $547,170 | – | 23,000 | +100.0% | 0.46% | – | |
| PHVS | Buy | PHARVARIS N V | $211,242 | -25.9% | 26,225 | +3.6% | 0.18% | -28.5% |
| Exit | AADI BIOSCIENCE INC | $0 | – | -64,739 | -100.0% | -0.72% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.